Multi-Site Coordination Process. Drafted by: Ester Dimayuga Page 1 of 18

Size: px
Start display at page:

Download "Multi-Site Coordination Process. Drafted by: Ester Dimayuga Page 1 of 18"

Transcription

1 Multi-Site Coordination Process Drafted by: Ester Dimayuga Page 1 of 18

2 MULTI-SITE COORDIATIO (MSC) REGULATOR PROCESS CTO-Regulatory notifies MSC of trial with UMCC as coordinating center MSC prepares site regulatory packages for sites Site regulatory packages ready to be sent to sites? IRB approval obtained? MSC sends regulatory package to sites Site processing of regulatory documents and contract Wait for IRB approval Local IRB approval obtained? Site contract finalized? MSC reviews documents submitted by site Site sends completed regulatory documents to MSC Questions/Discrepancies identified? MSC coordinates with CTO-IT to grant access to reference materials MSC gives site access to study reference materials MSC maintains site Regulatory file Drafted by: Ester Dimayuga Page 2 of 18

3 Regulatory Documents From MSC to each participating site: Protocol and amendment, if applicable Model Informed Consent Form Protocol Acceptance Form IRB approval letter CI approval letter, if applicable Investigational Brochure, if applicable Safety reports, if applicable Form 1572 Financial Disclosure, if applicable Site contracts (to be provided by Finance, if applicable) Site Study Contact List Drafted by: Ester Dimayuga Page 3 of 18

4 Regulatory Documents (continued) From each participating site to MSC after local IRB approval has been obtained: Signed Protocol Acceptance Form Local IRB approval of protocol/amendment Local informed consent form and local IRB approval letter IRB roster of membership Form 1572 Financial Disclosure of site primary investigator and co-investigator Current curriculum vitae of each study personnel Current medical licenses for primary investigator and co-investigator(s) Current CLIA Laboratory Certificate of Accreditation Current CAP Certification Current lab reference ranges Study contact list with contact information Drafted by: Ester Dimayuga Page 4 of 18

5 MULTI-SITE COORDIATIO (MSC) SITE PRE-IITIATIO PROCESS Regulatory notifies MSC of trial with UMCC as CC Are there other study reference materials from other study team members? Study team member prepares study reference materials MSC prepares study reference materials All study reference materials in Velos? Electronic copy of study reference materials provided to MSC Are the study reference materials final? Site processing of contract Site contract finalized? Local IRB approval obtained? Site processing of regulatory documents MSC coordinates with CTO-IT to grant study database access to site MSC gives site access to study reference materials Drafted by: Ester Dimayuga Page 5 of 18

6 Study Reference Materials From MSC to each participating center: Binder cover and spine AE/SAE Reporting Process Table of Contents CTEP AE Expedited Report, if applicable Contact Information Drug Ordering and Accountability Role of investigator, if applicable Pharmacy Dispensing Guidelines Protocol Data and Safety Monitoring Plan Study Enrollment Procedure Data and Safety Monitoring Report Screening and Enrollment Log otice of Protocol Deviation Delegation of Authority Sheets Specimen Handling Monitoring Visit Log Shipping Instructions and Forms Correspondence Specimen Labels Telephone Contact Report Supply Order Form Velos Data Entry Overview Lab Certifications Velos User Manual Lab ormal Values Patient Status Terminology Drafted by: Ester Dimayuga Page 6 of 18

7 MULTI-SITE COORDIATIO (MSC) STUD DOCUMETS FILIG PROCESS MSC creates or receives study document Is document in electronic format? Document conversion to electronic format Post document in appropriate folder in shared drive Is document a study reference material? Is document in PDF format? Document conversion to PDF format Post document in study database Drafted by: Ester Dimayuga Page 7 of 18

8 MULTI-SITE COORDIATIO (MSC) SITE IITIATIO PROCESS MSC gives site access to study reference materials MSC prepares presentation materials for site initiation Site downloads reference materials and creates study reference binder Presentation materials ready? Training database ready? IT finalizes training database Study reference binder ready? MSC coordinates initiation training with IT and site MSC informs site of date and attendees of training Site confirms date and attendees MSC conducts site initiation training Site faxes Attendance Sheet to MSC; site ready for enrollment MSC issues Site Initiation Visit Report no later than 1 week after completion of site initiation Drafted by: Ester Dimayuga Page 8 of 18

9 Site Initiation Meeting Topics Protocol Study design, requirements and compliance Subject Recruitment Exclusion and inclusion criteria Enrollment process Study Calendar Schedule of study procedures and assessments CRFs Design and completion Data collection and database maintenance Data clarification process, if applicable Source Data/Document Verification Guidelines Drug Supplies Receipt, dispensing, return and accountability Storage requirements, as necessary Drafted by: Ester Dimayuga Page 9 of 18

10 Site Initiation Meeting Topics (continued) Laboratory Logistics Sample collection and shipment AE/SAE Reporting Different required reports Processes and standards GCPs and applicable regulatory requirements Data and Safety Monitoring process and requirements IRB re-approval needs and processes Monitoring Frequency of visits and expectations Preparation for monitoring visits Audits and auditing processes Preparation for a site audit Records management and retention requirements Creation and maintenance of site master files Drafted by: Ester Dimayuga Page 10 of 18

11 Site Initiation Meeting Topics (continued) Issue resolution and communication process flow Review of site contact list and CTO-UMCC study directory Unblinding Process Reasons Required documentation Question and Answer Throughout the entire site initiation, encourage study staff to raise any questions or feedback they might have. It is possible for a question/issue to be unanswered or unresolved by the end of the site initiation. In such a case, assure the site that those would be followed-up on until they have been answered or resolved. Drafted by: Ester Dimayuga Page 11 of 18

12 Site Initiation Participants Recommended Site Participants: Principal investigator The principal investigator must make every effort to attend the site initiation. If not possible, the site s co-investigator should be in attendance. Site staff Study coordinator Study nurse Pharmacist All other study staff identified in the Delegation of Duties and Signature Log Drafted by: Ester Dimayuga Page 12 of 18

13 MULTI-SITE COORDIATIO (MSC) EROLLMET PROCESS Site screens a patient Site documents patient in Screening and Enrollment Log Is patient eligible? Site completes Eligibility Worksheet and obtains PI signature; provides source docs Site updates patient status in log as screen failure UMCC Registrar assigns patient study ID and notifies site of enrollment; logs patient on Master Enrollment Log, files enrollment documents Is documentation sufficient? UMCC Registrar reviews Eligibility Worksheets and source docs Site sends Eligibility Worksheets and source docs to UMCC Registrar Site updates patient status as enrolled; enters enrollment data into database Is there any deviation from protocol? Is protocol deviation first of its kind in the study? MSC forwards case to UM PI for review and approval Site completes otice of Protocol Deviation and obtains PI signature and related documents UM PI approves protocol deviation? MSC notifies site of UM PI decision Site sends Protocol Deviation and supporting documents to MSC Site updates patient status in log as screen failure Drafted by: Ester Dimayuga Page 13 of 18

14 MULTI-SITE COORDIATIO (MSC) SAE REPORTIG PROCESS Site has a reportable SAE Is study sponsored by CI? Site reports to CC: PI, Regulatory and MSC copied Site reports to sponsor, if required by protocol Site reports to local IRB Site reports to CI via AdEERS; PI and MSC copied Site reports to local IRB Site sends MSC copy of IRB s acknowledgement of receipt of SAE report MSC files report in site s Regulatory binder MSC forwards SAE report to CTO Regulatory contact MSC forwards SAE report to other participating sites MSC files report in site s Regulatory binder Regulatory contact notifies IRB via eresearch Drafted by: Ester Dimayuga Page 14 of 18

15 MULTI-SITE COORDIATIO (MSC) EARL CODE RELEASE PROCESS Site pharmacist completes Code Release Form Site investigator approves request for Code Release Site pharmacist sends form, documents/info to MSC MSC reviews paperwork: All information sent? Site pharmacist resolves deficiency MSC notifies site pharmacist of deficiency MSC obtains PI signature on Code Release Form MSC s site pharmacist of code release approval; copies site PI, CC s PI and statistician PI approves site request for early code release MSC notifies PI of site request for approval MSC faxes site a copy of signed Code Release Form Site pharmacist releases treatment code OL to site PI Drafted by: Ester Dimayuga Page 15 of 18

16 DATA AD SAFET MOITORIG PROCESS (only for investigator-initiated multi-site trials with no independent external DSMB) Protocol deviations Adverse events Patient accrual Protocol deviations Site completes Protocol Deviation Form Site completes Protocol Specific Data and Safety Monitoring Report Site submits completed report with pertinent documentation to MSC MSC forwards report and documents to DSMC DSMC provides reports and documents to DSMB - Drafted by: Ester Dimayuga Page 16 of 18

17 MULTI-SITE COORDIATIO (MSC) MOITORIG PROCESS MSC conducts site initiation Site ready for enrollment Site enrolls patients into study Actual visit to the site Telephone conference Investigator s Meeting Site has enrolled 5 patients? Study completed, terminated or cancelled? Site continues to enroll patients into the study MSC conducts monitoring visit; issues Monitoring Visit Report no later than 1 week after completion of visit MSC conducts site close-out MSC issues Close-Out Visit Report no later than 1 week after completion of visit Actual visit to the site Source docs and charts review Actual visit to the site Source docs and charts review Drafted by: Ester Dimayuga Page 17 of 18

18 QUALIT ASSURACE AD AUDIT On-site audit of selected patient records CTO/DSMB requests audit for a study Audit of source documents and research records at CC CI/DOD- sponsored study Investigator-initiated study CI audit of selected patient records at participating site CI audit of source documents and research records at Coordinating Center On-site audit of selected patient records Audit of source documents and research records at CC Site prepares for audit Site sends documents to CTO Site prepares for audit Site sends documents to CTO MSC notifies site of audit Site prepares documents MSC notifies site of audit Site prepares documents MSC notifies site of audit MSC notifies site of audit Drafted by: Ester Dimayuga Page 18 of 18

Regulatory Binder: Set-up and Maintenance

Regulatory Binder: Set-up and Maintenance Regulatory Binder: Set-up and Maintenance Introduction Federal and state regulations, institutional policy, and good clinical and research practices require investigators to maintain documents related

More information

Human Research Protection Program Good Clinical Practice Guidance for Investigators Regulatory File Essential Documents

Human Research Protection Program Good Clinical Practice Guidance for Investigators Regulatory File Essential Documents Guidance for s Regulatory File Essential s All principal investigators must maintain a regulatory binder or file system, which contains all study documentation. These records may be reviewed at the time

More information

Regulatory Document Guidelines for DMID Clinical Studies. Version Oct-2005

Regulatory Document Guidelines for DMID Clinical Studies. Version Oct-2005 Regulatory Document Guidelines for DMID Clinical Studies Version 3.0-5-Oct-2005 1 Regulatory File Document Guidelines Purpose: To aid DMID supported Investigators in establishing a file of essential documents

More information

Investigator Site File Index (Medical Devices)

Investigator Site File Index (Medical Devices) Study Title: Site Name/Number: REC Reference Number: Sponsor Reference Number: EudraCT Number: 1. Protocol (Clinical Investigation Plan) Current version plus all previous versions (or provide file note

More information

Regulatory Documentation and Submissions for C2012 Clinical Trials DCP SOP #1

Regulatory Documentation and Submissions for C2012 Clinical Trials DCP SOP #1 Regulatory Documentation and Submissions for C2012 Clinical Trials DCP SOP #1 Phone: 650.691.4400 Fax: 650.691.4410 Email: regulatory.ccsainc.com COMPLIANCE & STANDARDIZATION Rationale for Revision of

More information

Regulatory Binder Guidance

Regulatory Binder Guidance Regulatory Binder Guidance What is the purpose of a regulatory binder? Achieve and maintain regulatory compliance Ensure protection of human subjects and high standards of research Guidance for organization

More information

Investigator Site File Index (CTIMP)

Investigator Site File Index (CTIMP) Study Title: Site Name/Number: REC Reference Number: Sponsor Reference Number: EudraCT Number: 1. Protocol Current version plus all previous versions (or provide file note to detail location of previous

More information

STANDARD OPERATING PROCEDURE FOR RESEARCH. 17. Study Close Down

STANDARD OPERATING PROCEDURE FOR RESEARCH. 17. Study Close Down Basildon and Thurrock University Hospitals NHS FT Research & Development APPROVED STANDARD OPERATING PROCEDURE FOR RESEARCH 1. BACKGROUND 17. Study Close Down According to ICH Good Clinical Practice (GCP)

More information

ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL

ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL Assemble Essential Documents in Trial Master File (TMF) Appendix 1 ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL 8.2 Before the Clinical Phase of the Trial Commences During this planning stage

More information

Source And Regulatory Documentation for DMID Clinical Studies

Source And Regulatory Documentation for DMID Clinical Studies Source And Regulatory Documentation for DMID Clinical Studies Walt Jones RN, MPH Nurse Consultant Clinical Monitoring Coordinator OCRA, DMID, NIAID November, 2007 Source Data Defined All information in

More information

POST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312)

POST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312) POST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312) Purpose: Investigators who initiate and submit an IND application to the FDA assume the responsibilities of both the

More information

Guidelines for Setting Up a Regulatory Binder

Guidelines for Setting Up a Regulatory Binder Guidelines for Setting Up a Regulatory Binder Prepare for an audit Georgamaly Estronza, MS UPR - Medical Sciences Campus IRB Administrator - Compliance Officer Email: georgamaly.estronza@upr.edu Introduction

More information

Compliance and Quality Monitoring: What, Why, When, and How

Compliance and Quality Monitoring: What, Why, When, and How Compliance and Quality Monitoring: What, Why, When, and How Jeanna Julo, BA, BA, CCRP Assistant Director, Clinical Data Management & Quality Controls, Auditing & Training Research Institute, University

More information

LOUGHBOROUGH UNIVERSITY RESEARCH OFFICE STANDARD OPERATING PROCEDURE. Loughborough University (LU) Research Office

LOUGHBOROUGH UNIVERSITY RESEARCH OFFICE STANDARD OPERATING PROCEDURE. Loughborough University (LU) Research Office LOUGHBOROUGH UNIVERSITY RESEARCH OFFICE STANDARD OPERATING PROCEDURE Loughborough University (LU) Research Office SOP 1024 LU Study Closedown and End of Study Reporting for NHS Research Sponsored by Loughborough

More information

Objectives. The Regulatory Binder = Investigator Site File= Trial Center File 8/16/2010. Essential Documents: Maintaining the Site's Regulatory Binder

Objectives. The Regulatory Binder = Investigator Site File= Trial Center File 8/16/2010. Essential Documents: Maintaining the Site's Regulatory Binder Essential Documents: Maintaining the Site's Regulatory Binder How to Manage the Essential Documents for the Investigator and Study Site Objectives Describe the importance of maintaining the Regulatory

More information

ESSENTIAL DOCUMENTS DURING THE CLINICAL CONDUCT OF THE TRIAL

ESSENTIAL DOCUMENTS DURING THE CLINICAL CONDUCT OF THE TRIAL ESSENTIAL DOCUMENTS DURING THE CLINICAL CONDUCT OF THE TRIAL THIS INFORMATION SHEET (ISR-RG-014) HAS BEEN TAKEN DIRECTLY FROM THE ICH- GUIDELINE* WITH ADDITIONAL COMMENTS ADDED BY THE RESEARCH GOVERNANCE

More information

Presented by NC TraCS Institute UNC Office of Clinical Trials UNC Network for Research Professionals

Presented by NC TraCS Institute UNC Office of Clinical Trials UNC Network for Research Professionals ORIENTATION FOR NEW CLINICAL RESEARCH COORDINATORS Presented by NC TraCS Institute UNC Office of Clinical Trials UNC Network for Research Professionals Overall Agenda for Orientation Module 1: Introduction

More information

FDA Sponsor and Investigator Responsibility Checklist

FDA Sponsor and Investigator Responsibility Checklist FDA Sponsor and Investigator Responsibility Checklist Principal Investigator: Study Name: CPHS #: IND/IDE #: Name of IND/IDE holder: The following checklist is created based on the Sponsor and Investigator

More information

and Study Initiation

and Study Initiation 10 STUDY SPECIFIC PRE-IMPLEMENTATION, SITE ACTIVATION AND STUDY INITIATION... 2 10.1 Clinical Trials Agreement... 4 10.2 Study Product Acquisition and Shipment to Sites... 5 10.3 Study-specific Preparatory,

More information

and Study Initiation

and Study Initiation 10 STUDY SPECIFIC PRE-IMPLEMENTATION, SITE ACTIVATION AND STUDY INITIATION... 2 10.1 Clinical Trials Agreement... 4 10.2 Study Product Acquisition and Shipment to Sites... 5 10.3 Study-specific Preparatory,

More information

Source Documents and Regulatory Binders October 6, 2016

Source Documents and Regulatory Binders October 6, 2016 Source Documents and Regulatory Binders October 6, 2016 Lisa Wilson, Regulatory Lead, Clinical Trials Office and Mark Alger, CRC, Clinical Trials Office Essential Documents AKA: the stuff in the Reg Binder

More information

Louise Brook Clinical Trials Quality Monitor. Date

Louise Brook Clinical Trials Quality Monitor. Date Details: Author: Louise Brook Clinical Trials Quality Monitor SOP Pages: 12 Version No. of replaced SOP: Effective date of replaced SOP: NA NA Approval: Version No: of the SOP being approved. Name of person

More information

Standard Operating Procedures Guidelines for Good Clinical Practice

Standard Operating Procedures Guidelines for Good Clinical Practice SOP # CRSC-105 Effective Date 10-22-2013 Version # 1 Version Date 7-30-2013 Standard Operating Procedures Guidelines for Good Clinical Practice Purpose: This SOP outlines the steps required to follow FDA

More information

STANDARD OPERATING PROCEDURE. STH Researcher. Investigator Site File

STANDARD OPERATING PROCEDURE. STH Researcher. Investigator Site File Research Department STANDARD OPERATING PROCEDURE STH Researcher SOP History CSUH 00/016 SOP Number A116 Created STH Research Department (TL) Reviewed by STH Research Department (AL) 06 August 2009 Superseded

More information

Objectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents

Objectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents Data Management in Clinical Trials Introduction to the Principles and Practice of Clinical Research January 24, 2011 Diane St. Germain, RN, MS, CRNP Nurse Consultant Division of Cancer Prevention National

More information

4.2. Investigator Regulatory Binder: Files, usually a binder, maintained by the investigator at the investigative site.

4.2. Investigator Regulatory Binder: Files, usually a binder, maintained by the investigator at the investigative site. POLICY #: RCO-203 Page: 1 of 7 1. POLICY STATEMENT: Essential regulatory documents will be on maintained for research sponsored by or conducted at Dana-Farber/Harvard Cancer Center (DF/HCC) to assure compliance

More information

FDA Audit Preparation

FDA Audit Preparation Duke University Office of Audit, Risk and Compliance (OARC) FDA Audit Preparation Margaret M. Groves, JD, CRA, CCRP, CHRC Associate Compliance Officer, Research Compliance Assurance (RCA) External audits

More information

1 The Clinical Research Coordinator (CRC)... 1

1 The Clinical Research Coordinator (CRC)... 1 TABLE OF CONTENTS Dedication... iii Introduction... xi 1 The Clinical Research Coordinator (CRC)... 1 Role and Responsibilities of the CRC...1 Personality and Skills... 3 Where Do CRCs Work?... 3 CRC Responsibilities...

More information

FRAMEWORK OF CHARACTERISTICS OF A QUALIFIED SITE TEAM: How Does Yours Measure Up?

FRAMEWORK OF CHARACTERISTICS OF A QUALIFIED SITE TEAM: How Does Yours Measure Up? FRAMEWORK OF CHARACTERISTICS OF A QUALIFIED SITE TEAM: How Does Yours Measure Up? The following framework of characteristics focuses on attributes that are within the control of investigators and their

More information

Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd.

Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd. Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd. Copyright 2009 - Pharmaceutical Research & Manufacturers Association 1 Overview Audit ICH-GCP,

More information

I. Purpose. II. Definitions. Last Approval Date

I. Purpose. II. Definitions. Last Approval Date Investigational Drugs and Biologics Page 1 of 13 I. Purpose The purpose of this policy is to establish procedures for the proper control, storage, use and handling of investigational drugs and biologics

More information

RESEARCH AUDIT Standard Operating Procedure

RESEARCH AUDIT Standard Operating Procedure Reference Number: UHB 236 Version Number: 2 Date of Next Review: 17 th Oct 2020 Previous Trust/LHB Reference Number: N/A RESEARCH AUDIT Standard Operating Procedure Introduction and Aim As a legal Sponsor

More information

OFFICE FOR RESEACH PROCEDURE. Site Initiation and Close-out

OFFICE FOR RESEACH PROCEDURE. Site Initiation and Close-out OFFICE FOR RESEACH PROCEDURE Site Initiation and Close-out 1. Purpose: To describe the procedures related to site initiation and close-out of a clinical trial. 2. Scope: Applicable to all phases of clinical

More information

Trial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products

Trial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products 1 Trial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products SECTION TITLE DOCUMENTS 1. Contact List Including details of relevant study site staff, responsible

More information

PHARMACY, MEDICINES & POISONS BOARD

PHARMACY, MEDICINES & POISONS BOARD PHARMACY, MEDICINES & POISONS BOARD PHARMACY GUIDELINES FOR INVESTIGATIONAL DRUGS A. Purpose These guidelines are principally derived and adapted from guidelines from various sources within the SADC region.

More information

ROLE OF THE RESEARCH COORDINATOR Study Startup Best Practices May 2016

ROLE OF THE RESEARCH COORDINATOR Study Startup Best Practices May 2016 UCLA CTSI WELCOME TO ONLINE TRAINING FOR CLINICAL RESEARCH COORDINATORS ROLE OF THE RESEARCH COORDINATOR Study Startup Best Practices May 2016 Objectives Define the sponsor of a clinical trial and learn

More information

R&D Manager Hillingdon Hospital. Revision History Effective Date Reason For Change. recommendations Version no:

R&D Manager Hillingdon Hospital. Revision History Effective Date Reason For Change. recommendations Version no: Research as a Participating site STANDARD OPERATING PROCEDURE FOR OVERSIGHT SOP No: P08/PF2 V2 Effective Date: 31 st July 2013 Supersedes: P08/PF2 Revision Date: 31 st March 2014 Author: Position: Approved

More information

Clinical Trial Basics:

Clinical Trial Basics: Clinical Trial Basics: Components and Responsibilities Pre-Award Aida Nana Ama Manu, Project Coordinator Four Main Components Non-Disclosure Agreements Institutional Review Board Application Clinical Trial

More information

Study Files and Filing

Study Files and Filing Study Files and Filing The current version of all Hillingdon Hospital R&D Guidance Documents and Standard Operating Procedures are available from the R&D Intranet and Internet sites: www.ths.nhs.uk/departments/research/research.htm

More information

ELEMENTS OF A DATA MONITORING PLAN

ELEMENTS OF A DATA MONITORING PLAN ELEMENTS OF A DATA MONITORING PLAN Definitions Data Monitoring: The regular evaluation of data and documentation collected during a study to ensure both adherence to the approved investigative plan and

More information

SELF-ASSESSMENT CHECKLIST

SELF-ASSESSMENT CHECKLIST SELF-ASSESSMENT CHECKLIST SECTION 1: REGULATORY DOCUMENTATION Staff Documentation 1. Are all versions of the IRB approved protocol on file (including most recent)? 2. Are there CVs/biosketches of PI, Co-Is,

More information

CANCER CENTER SCIENTIFIC REVIEW COMMITTEE

CANCER CENTER SCIENTIFIC REVIEW COMMITTEE CANCER CENTER SCIENTIFIC REVIEW COMMITTEE The Clinical Scientific Review Committee (SRC) at The Medical College of Wisconsin Cancer Center plays a vital role in protocol review and monitoring to ensure

More information

Site Initiation and Activation

Site Initiation and Activation Site Initiation and Activation Clinical Trials SOP Reference ID: Noclor/Spon/S05/01 Version Number 1.0 Effective Date: 23 rd February 2016 It is the responsibility of all users of this SOP to ensure that

More information

1. POLICY STATEMENT: 2. BACKGROUND:

1. POLICY STATEMENT: 2. BACKGROUND: POLICY #: RCO-201 Page: 1 of 5 1. POLICY STATEMENT: All Food and Drug Administration (FDA) regulated research conducted under an Investigational New Drug Application (IND) and managed within DF/HCC requires

More information

INVESTIGATIONAL DRUG MANAGEMENT OVERVIEW

INVESTIGATIONAL DRUG MANAGEMENT OVERVIEW NORTHWELL HEALTH OFFICE OF RESEARCH COMPLIANCE STUDY FEASIBILITY AND APPROVAL Where can I learn about the investigational drug? Protocol Investigator s brochure Product insert or prescribing information

More information

Introduction to Clinical Research

Introduction to Clinical Research Introduction to Clinical Research What is Clinical Research? Clinical research is medical research that involves people like you. People volunteer to participate in carefully conducted investigations that

More information

Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework

Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework 1 Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework Mandy Morneault Research Compliance Monitor University of Washington Institute of Translational Health

More information

Hub Performance Assessment

Hub Performance Assessment Hub Performance Assessment Hub complex performance assessment will be assessed with a standardized report card mechanism. The report card draws on data quality reports, enrollment reports, and monitoring

More information

FDA Audit Preparation

FDA Audit Preparation Duke University Ethics and Compliance Office FDA Audit Preparation Margaret M. Groves, JD, CRA, CCRP, CHRC Director, CTQA Agenda External audits Best practices to get ready for audits 2 External Audits

More information

Investigator-Initiated INDs

Investigator-Initiated INDs Investigator-Initiated INDs Marjorie Small, RN, CCRC Office of Clinical Research 23 May 2011 PPHS/IRB Research Grand Rounds Outline of Presentation I. What is an IND? II. Code of Federal Regulations III.

More information

STANDARD OPERATING PROCEDURE SOP 410. Set up and Initiation of an Investigator Site

STANDARD OPERATING PROCEDURE SOP 410. Set up and Initiation of an Investigator Site STANDARD OPERATING PROCEDURE SOP 410 Set up and Initiation of an Investigator Site Version 1.2 Version date 4.01.2017 Effective date 5.07.2017 Number of pages 13 Review date July 2019 Author Role NNUH

More information

National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services

National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services The Division of Microbiology and Infectious Diseases (DMID), National Institute

More information

Investigational New Drug Development Steps for CRCs

Investigational New Drug Development Steps for CRCs Investigational New Drug Development Steps for CRCs Natalie Nardone, PhD Program Manager, Department of Medicine CRC Instructor, Office of Clinical Research Contact: natalie.nardone@ucsf.edu Learning Objectives

More information

Preparing for Close-Out of Studies and Sites

Preparing for Close-Out of Studies and Sites Preparing for Close-Out of Studies and Sites Presented by: Christie Thomas, MPH, CCRA Matthew Wright, BS, CCRP Dikla Blumberg, PhD CTN WEB SEMINAR SERIES: A FORUM TO EXCHANGE RESEARCH KNOWLEDGE Produced

More information

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor. POLICY #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional

More information

DANA-FARBER / HARVARD CANCER CENTER STANDARD OPERATING PROCEDURES FOR CLINICAL RESEARCH

DANA-FARBER / HARVARD CANCER CENTER STANDARD OPERATING PROCEDURES FOR CLINICAL RESEARCH DANA-FARBER / HARVARD CANCER CENTER STANDARD OPERATING PROCEDURES FOR CLINICAL RESEARCH TITLE: SOP #: QA-706 Page: 1 of 7 Applicable Regulations & Guidelines: 21 CFR 312.60 General Responsibilities of

More information

\\NAS1\George\Docs\SoCRA\CCRP communications\study guide management

\\NAS1\George\Docs\SoCRA\CCRP communications\study guide management Five Content Areas Percent of Scored Test Items (Range) in Each Area This table shows the percent of scored test questions that are included in each major content area. Five Content Areas Ethical Principles

More information

Quality Assurance QA STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits

Quality Assurance QA STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits Quality Assurance QA 601.01 STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature and Date) Approval: Frederick

More information

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor. SOP #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional responsibilities

More information

Annex IV to guidance for the conduct of good clinical practice inspections sponsor and CRO

Annex IV to guidance for the conduct of good clinical practice inspections sponsor and CRO 23 August 2017 EMA/431267/2016 Annex IV to guidance for the conduct of good clinical practice inspections sponsor Adopted by GCP Inspectors Working Group (GCP IWG) 29 November 2017 Keywords GCP inspection,

More information

ROLE OF THE RESEARCH COORDINATOR Investigational New Drug Application-Sponsor Responsibilities 21CFR Part , subpart D

ROLE OF THE RESEARCH COORDINATOR Investigational New Drug Application-Sponsor Responsibilities 21CFR Part , subpart D Clinical and Translational Science Institute / CTSI at the University of California, San Francisco Welcome to Online Training for Clinical Research Coordinators ROLE OF THE RESEARCH COORDINATOR Investigational

More information

Conducting and reporting a GCP Inspection. Gunnar Danielsson Medical Products Agency

Conducting and reporting a GCP Inspection. Gunnar Danielsson Medical Products Agency Conducting and reporting a GCP Inspection Gunnar Danielsson Medical Products Agency Preparation for an inspection Inspection plan Create worksheets for the inspection general project specific study specific

More information

ARCHIVING REGULATIONS

ARCHIVING REGULATIONS The pocket guide to ARCHIVING REGULATIONS How to Maintain Compliance & Drive Efficiencies at Study Closeout Pocket Guide Pocket Guide to Archiving Regulations Being able to easily manage the site archive

More information

Date: 23 rd December 2014 Version 5 Page 1 of 8 STANDARD OPERATING PROCEDURE FOR TRIAL INITIATION AND SITE SET UP (NWORTH 3.03)

Date: 23 rd December 2014 Version 5 Page 1 of 8 STANDARD OPERATING PROCEDURE FOR TRIAL INITIATION AND SITE SET UP (NWORTH 3.03) Page 1 of 8 STANDARD OPERATING PROCEDURE FOR TRIAL INITIATION AND SITE SET UP (NWORTH 3.03) Approvals Principal Author Name: D. Skelhorn Signature: D. Skelhorn Date: 22/12/2014 Quality Assurance Officer

More information

Code break is also known as breaking the blind and involves un-blinding a participant so that the treatment allocation is made known.

Code break is also known as breaking the blind and involves un-blinding a participant so that the treatment allocation is made known. 1. INTRODUCTION This SOP has been produced in accordance with Medicines for Human Use (Clinical Trials) Regulations 2004. This SOP will outline the procedure for breaking the study code in a NUH sponsored

More information

Investigator s Responsibility

Investigator s Responsibility Investigator s Responsibility Introduction Investigator s Qualifications Clinical Trial Agreement Adequate Resources Medical Care of Trial Subjects Communication with IRB/IEC Study Initiation Patient Recruitment

More information

Standard Operating Procedure

Standard Operating Procedure Standard Operating Procedure Number: UM/UoM TMF/SOP08/6.0 Title: The Creation and Maintenance of Trial Master Files and Essential Documentation Version: 6.0 () Effective Date: Author: Mrs Catherine Barrow

More information

The European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA:

The European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: The European Medicines Agency Inspections London, 20 September 2007 EMEA/INS/GCP/197221/2005 Procedure no.: INS/GCP/3/IV ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: SPONSOR

More information

Conducting Clinical Trials of Investigational Medicinal Products

Conducting Clinical Trials of Investigational Medicinal Products Title: Outcome Statement: Written By: Reviewed By: Conducting Clinical Trials of Investigational Medicinal Products Researchers in the Trust and research partners will be informed about the procedures

More information

Human Research Audit Program. Gabrielle Gaspard, MPH, CCRC Assistant Director, Human Research Compliance

Human Research Audit Program. Gabrielle Gaspard, MPH, CCRC Assistant Director, Human Research Compliance Human Research Audit Program Gabrielle Gaspard, MPH, CCRC Assistant Director, Human Research Compliance Monday, September 11, 2017 Objectives 1. Understand the purpose of the audit program 2. Identify

More information

Demystifying Audits. Audits and Audit Preparation 5/23/2016. What is an Audit?

Demystifying Audits. Audits and Audit Preparation 5/23/2016. What is an Audit? Demystifying Audits Darlene Kitterman, MBA Director, Investigator Support & Integration Services OCTRI May 26, 2016 Audits and Audit Preparation What is an Audit? A systematic and independent examination

More information

Standard Operating Procedure for Archiving

Standard Operating Procedure for Archiving Standard Operating Procedure for Archiving SOP name: NWORTH07/19 archiving Version 2 Authorship Team: Angela Gliddon & Rhiannon Whitaker Meeting date reviewed 16 th April 2008 Designated NWORTH member

More information

Standard Operating Procedure

Standard Operating Procedure Standard Operating Procedure Title: Clinical Site Monitoring Status: PRIVATE Author Name: Audrey Strader Approver Name: Christine Kubiak Document no.: CSM 02 Effective date: 11/01/2016 Review Date (if

More information

Show Me Your Docs! A REVIEW OF UNIVERSITY OF PITTSBURGH GUIDELINE: STUDY DOCUMENTATION FOR FDA REGULATED RESEARCH

Show Me Your Docs! A REVIEW OF UNIVERSITY OF PITTSBURGH GUIDELINE: STUDY DOCUMENTATION FOR FDA REGULATED RESEARCH Show Me Your Docs! A REVIEW OF UNIVERSITY OF PITTSBURGH GUIDELINE: STUDY DOCUMENTATION FOR FDA REGULATED RESEARCH Speakers Kelly Dornin-Koss, MPPM, RN, CCRC Director Education and Compliance for Human

More information

Standard Operating Procedure. GCP Auditing of Research Studies

Standard Operating Procedure. GCP Auditing of Research Studies Standard Operating Procedure SOP number: SOP full title: SOP-JRO-16-003 GCP Auditing of Research Studies SOP effective: 09 June 2017 Review date: 09 June 2019 SOP author signature: SIGNED COPY HELD WITHIN

More information

Sponsor-Investigator Responsibilities In Clinical Trials

Sponsor-Investigator Responsibilities In Clinical Trials In Clinical Trials Margaret Huber, RN, BSN, CHRC Compliance Manager The lecturer has no conflicts for this presentation 9/23/2015 Objectives Define terms sponsor, investigator, and sponsor-investigator.

More information

DRUG ORDERING AND MAINTENANCE

DRUG ORDERING AND MAINTENANCE AND MAINTENANCE Disclaimer: Please note that the instructions provided in this chapter only apply to agents provided by the Pharmaceutical Management Branch (PMB), of Cancer Therapy Evaluation Program

More information

Implementing Good Clinical Practice at an Academic Research Institution

Implementing Good Clinical Practice at an Academic Research Institution Implementing Good Clinical Practice at an Academic Research Institution Maintaining Essential Documents Partners Human Research Quality Improvement (QI) Program Stephen W. Hayes Outline Significance of

More information

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL STUDY PROTOCOL CHAPTER 14 REVISED: OCTOBER 2015

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL STUDY PROTOCOL CHAPTER 14 REVISED: OCTOBER 2015 THE STUDY PROTOCOL The study protocol is a written document detailing how a clinical trial is conducted. The elements of a protocol include: 1. Trial design and organization; 2. Study objectives; 3. Background

More information

DRUG ORDERING AND MAINTENANCE

DRUG ORDERING AND MAINTENANCE AND MAINTENANCE Disclaimer: Please note that the instructions provided in this chapter mainly apply to agents provided by the Pharmaceutical Management Branch (PMB), of Cancer Therapy Evaluation Program

More information

Quality Control in Clinical Trials Blinding, Clinical Event Committees, Core Labs, and Data Standards

Quality Control in Clinical Trials Blinding, Clinical Event Committees, Core Labs, and Data Standards Quality Control in Clinical Trials Blinding, Clinical Event Committees, Core Labs, and Data Standards Roxana Mehran Columbia University Medical Center Cardiovascular Research Foundation Disclosures Research

More information

SOP NUMBER: SC-404 Page 1 of 3

SOP NUMBER: SC-404 Page 1 of 3 STANDARD OPERATING PROCEDURE (SOP) FOR CLINICAL RESEARCH Last Revised: 1/2016 Prior Version: None Title: Transporting Investigational Product to Other Sites SOP NUMBER: SC-404 Page 1 of 3 1. PURPOSE: UHCMC

More information

Regulatory Visits, Audits and Investigations

Regulatory Visits, Audits and Investigations Regulatory Visits, Audits and Investigations The Role of the Compliance Officer Carole A. Klove, JD, RN, CHRC Juliann Tenney, JD, CHRC Welcome! The content of this presentation does not necessarily represent

More information

IRB-GCP and Timelines. Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October th, 2010

IRB-GCP and Timelines. Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October th, 2010 IRB-GCP and Timelines Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October 11-14 th, 2010 1 Factors that affect Timelines Finalized Protocol Finalized

More information

Standard Operating Procedures (SOP) Research and Development Office

Standard Operating Procedures (SOP) Research and Development Office Standard Operating Procedures (SOP) Research and Development Office Title of SOP: Essential Documentation and Creation and Maintenance of Trial Master File SOP Number: 13 Version Number: 2.0 Supercedes:

More information

Standard Operating Procedures (SOPs) for. Clinical Research Personnel Part 16. Summary

Standard Operating Procedures (SOPs) for. Clinical Research Personnel Part 16. Summary Standard Operating Procedures for Clinical Research Personnel Part 16 Wendy Bohaychuk and Graham Ball GCRP Consultants, Lakehurst General Delivery, Ontario, Canada KOL 2JO Summary This is the 16th in a

More information

Compliance Program Guidance Manuals (CPGMs) -1-

Compliance Program Guidance Manuals (CPGMs) -1- Inspector s Preparation for a CI Inspection: FDA Compliance Program & the Records Inventory Jean Toth-Allen, Ph.D. APEC GCP Inspection Workshop May 28, 2008 Compliance Program Guidance Manuals (CPGMs)

More information

Clinical Research with Drugs/Biologics and Devices & Good Clinical Practices

Clinical Research with Drugs/Biologics and Devices & Good Clinical Practices Clinical Research with Drugs/Biologics and Devices & Good Clinical Practices Jason Jobson, BLS, CCRP Research Compliance Officer Oklahoma City VA Medical Center October 2017 Goals Investigational New Drug

More information

University of Virginia Cancer Center

University of Virginia Cancer Center University of Virginia Cancer Center Data and Safety Monitoring Plan for Clinical Research March 18, 2016 Approved: National Cancer Institute April 14 th, 2016 Table of Contents 1. Introduction... 3 2.

More information

Clinical Trials Management for Molecular Diagnostics. April 2016

Clinical Trials Management for Molecular Diagnostics. April 2016 Clinical Trials Management for Molecular Diagnostics April 2016 Clinical Operations Responsibilities Accrue samples that have proper informed consent for use Retrospective cohorts Remnant samples Prospective

More information

US Special Operations Command Human Research Protection Office

US Special Operations Command Human Research Protection Office S- US Special Operations Command Human Research Protection Office Human Research Protocol Submission Form for Headquarters Level Administrative Review of Extramural* Research PURPOSE: All United States

More information

Recommendations for Strengthening the Investigator Site Community

Recommendations for Strengthening the Investigator Site Community Recommendations for Strengthening the Investigator Site Community October 2017 CTTI MISSION: To develop and drive adoption of practices that will increase the quality and efficiency of clinical trials

More information

Sponsor/Investigator Responsibilities

Sponsor/Investigator Responsibilities Sponsor/Investigator Responsibilities Marian Serge, RN Division of Bioresearch Monitoring Office of Compliance Center for Devices and Radiological Health Food and Drug Administration Marian.Serge@fda.hhs.gov

More information

IMP Management and Accountability

IMP Management and Accountability This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document

More information

UC Irvine s Clinical Research Coordinator Certification Preparation Series PI Roles and Responsibilities

UC Irvine s Clinical Research Coordinator Certification Preparation Series PI Roles and Responsibilities UC Irvine s Clinical Research Coordinator Certification Preparation Series PI Roles and Responsibilities BEVERLY ALGER, CCRP, CHRC Research Compliance Officer Office of Research Compliance November 2016

More information

Data Management & Case Report Form Development in Clinical Trials. Introduction to the Principles and Practice of Clinical Research.

Data Management & Case Report Form Development in Clinical Trials. Introduction to the Principles and Practice of Clinical Research. Data Management & Case Report Form Development in Clinical Trials Introduction to the Principles and Practice of Clinical Research February 2, 2016 Marge Good, RN, MPH, OCN Nurse Consultant Division of

More information

Human Research Protection Program Policy

Human Research Protection Program Policy Adopted: 11/2005 Revised: 03/2014 Page: 1 of 6 RIGHTS AND RESPONSIBILITIES OF PRINCIPAL INVESTIGATORS IN HUMAN SUBJECTS RESEARCH POLICY Each research study will have a Principal Investigator (PI) and may

More information

NEUROENDOVASCULAR TRIALS

NEUROENDOVASCULAR TRIALS 1 NEUROENDOVASCULAR TRIALS Understanding your Research Role in Stroke and Device Trials Tuesday, June 09, 2015 2 Biography Christy Anton is a Clinical Research Coordinator at Rush University Medical Center.

More information

Study Start-Up SS STANDARD OPERATING PROCEDURE FOR Investigator Selection

Study Start-Up SS STANDARD OPERATING PROCEDURE FOR Investigator Selection Effective date of version: April 01, 2012 Study Start-Up SS 202.00 STANDARD OPERATING PROCEDURE FOR Investigator Selection Approval: Nancy M. Paris, MS, FACHE President and CEO 08 March 2012 (Signature

More information

Date: 21 st May 2014 Version: 5 Page 1 of 11. Principal Author Name D. Skelhorn Signature: D. Skelhorn Date: 22 nd May 2014

Date: 21 st May 2014 Version: 5 Page 1 of 11. Principal Author Name D. Skelhorn Signature: D. Skelhorn Date: 22 nd May 2014 Date: 21 st May 2014 Version: 5 Page 1 of 11 STANDARD OPERATING PROCEDURE FOR MONITORING CLINICAL TRIALS (NWORTH 3.07) Approvals Principal Author Name D. Skelhorn Signature: D. Skelhorn Date: 22 nd May

More information